| Cash Flow | 2025-07-31 |
|---|---|
| Purchase of equipment | 0 |
| Net cash used in investing activities | 0 |
| Interest expense - debt discount | 0 |
| Net loss | -2,702,684 |
| Depreciation expense | 27,685 |
| Stock-based compensation to employees and consultants | 42,902 |
| Prepaid expenses and other current assets | 79,239 |
| Accounts payable and accrued liabilities | 348,550 |
| Net cash used in operating activities | -2,362,786 |
| Net proceeds from the issuance of preferred stock, net | 4,035,000 |
| Net cash provided by financing activities | 4,035,000 |
| Net increase in cash | 1,672,214 |
Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro, Inc. (ALZN)